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Clinical development programs are increasingly designing trials and timelines with extra degrees of flexibility to 
allow for acceleration based on early positive data.  It is becoming more common that a program in Phase I can 
plan for filing a Biological License Application in less then five years given a certain set of aggressive 
assumptions.  This often places CMC activities on a critical and potentially risky path requiring a large resource 
commitment at an early stage of clinical development when the likelihood of commercial launch remains low. 
  
In this presentation we explore a case study for one such program that demonstrated both a low supply demand 
and limited clinical data, but also has the potential for a fast-to-market strategy gated to positive clinical results.  
We introduce the concept of a Registration Enabling Campaign (REC) conducted in parallel with a traditional 
Phase III supply campaign that would supply the Registration Batches for a Biological License Application, but 
also eliminate the need for a traditional PPQ campaign.  While this initially requires an early investment prior to 
Phase III, it significantly reduces the resources required for a traditional qualification campaign that would be 
otherwise discarded for a low volume product. 
 
We will present the strategy for required prospective studies needed to support a Phase III-REC, rationales for 
study deferrals and overall risks associated with analytical quality control systems that must be leveraged at a 
very early phase in development. 
 
 
